Citations

Showing 10 of 108104 citations.

Improved Survival after Acute Kidney Injury
Kashani, Kianoush , Rule, Andrew D. , Rule, Andrew D , Kashani, Kianoush B

Mayo Clinic

Clinical Journal of the American Society of Nephrology | February 7, 2022 | Volume: 17 | Issue: 2 | Pages: 179-181

10.2215/cjn.16351221 | PMID 35131925 Get It

An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials
HaDuong, Josephine H. , Heske, Christine M. , Allen‐Rhoades, Wendy , Xue, Wei , Teot, Lisa A., Rodeberg, David A. , Donaldson, Sarah S. , Hawkins, Douglas S. , Venkatramani, Rajkumar , Hawkins, Douglas S , Rodeberg, David A , Donaldson, Sarah S , Allen-Rhoades, Wendy A , Weiss, Aaron R.

Mayo Clinic

Pediatric Blood & Cancer | February 7, 2022 | Volume: 69 | Issue: 4 | Pages: No page available

10.1002/pbc.29511 | PMID 35129294 Get It

AbstractChildren and adolescents with rhabdomyosarcoma (RMS) comprise a heterogeneous population with variable overall survival rates ranging between approximately 6% and 100% depending on defined risk factors. Although the risk stratification of patients has been refined across five decades of collaborative group studies, molecular prognostic biomarkers beyond FOXO1 fusion status have yet to be incorporated prospectively in upfront risk‐based therapy assignments. This review describes the evolution of risk‐based therapy and the current risk stratification, defines a new risk stratification incorporating novel biomarkers, and provides the rationale for the current and upcoming Children's Oncology Group RMS studies.
Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
Pelkmans, Wiesje , Vromen, Eleonora M. , Dicks, Ellen , Teunissen, Charlotte E. , Barkhof, Frederik , Tijms, Betty M. , Initiative, for the Alzheimer’s Disease Neuroimaging, Teunissen, Charlotte E , Tijms, Betty M , Barkhof, Frederik , Scheltens, Philip , Flier, Wiesje M. van der , Initiative, for the Alzheimer’s Disease Neuroimaging

Mayo Clinic

Brain Communications | February 7, 2022 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcac026 | PMID 35310828 Get It

AbstractIndividuals with prodromal Alzheimer’s disease show considerable variability in rates of cognitive decline, which hampers the ability to detect potential treatment effects in clinical trials. Prognostic markers to select those individuals who will decline rapidly within a trial time frame are needed. Brain network measures based on grey matter covariance patterns have been associated with future cognitive decline in Alzheimer’s disease. In this longitudinal cohort study, we investigated whether cut-offs for grey matter networks could be derived to detect fast disease progression at an individual level. We further tested whether detection was improved by adding other biomarkers known to be associated with future cognitive decline [i.e. CSF tau phosphorylated at threonine 181 (p-tau181) levels and hippocampal volume]. We selected individuals with mild cognitive impairment and abnormal CSF amyloid β1–42 levels from the Amsterdam Dementia Cohort and the Alzheimer’s Disease Neuroimaging Initiative, when they had available baseline structural MRI and clinical follow-up. The outcome was progression to dementia within 2 years. We determined prognostic cut-offs for grey matter network properties (gamma, lambda and small-world coefficient) using time-dependent receiver operating characteristic analysis in the Amsterdam Dementia Cohort. We tested the generalization of cut-offs in the Alzheimer’s Disease Neuroimaging Initiative, using logistic regression analysis and classification statistics. We further tested whether combining these with CSF p-tau181 and hippocampal volume improved the detection of fast decliners. We observed that within 2 years, 24.6% (Amsterdam Dementia Cohort, n = 244) and 34.0% (Alzheimer’s Disease Neuroimaging Initiative, n = 247) of prodromal Alzheimer’s disease patients progressed to dementia. Using the grey matter network cut-offs for progression, we could detect fast progressors with 65% accuracy in the Alzheimer’s Disease Neuroimaging Initiative. Combining grey matter network measures with CSF p-tau and hippocampal volume resulted in the best model fit for classification of rapid decliners, increasing detecting accuracy to 72%. These data suggest that single-subject grey matter connectivity networks indicative of a more random network organization can contribute to identifying prodromal Alzheimer’s disease individuals who will show rapid disease progression. Moreover, we found that combined with p-tau and hippocampal volume this resulted in the highest accuracy. This could facilitate clinical trials by increasing chances to detect effects on clinical outcome measures.
Vaccination against COVID‐19 decreases hospitalizations in patients with cirrhosis: Results from a nationwide analysis
Díaz, Luis Antonio , Lazo, Mariana , Kamath, Patrick S. , Arab, Juan Pablo , Arab, Juan P , Díaz, Luis A , Lazo, Mariana , Fuentes–López, Eduardo , Arrese, Marco

Mayo Clinic

Liver International | February 7, 2022 | Volume: 42 | Issue: 4 | Pages: 942-944

10.1111/liv.15193 | PMID 35129285 Get It

Unusual presentation of stiff-person syndrome in a patient with type 1 diabetes mellitus
Munipalli, Bala, Shah, Jaimin S

Mayo Clinic

BMJ Case Reports | February 7, 2022 | Volume: 15 | Issue: 2 | Pages: e247482

10.1136/bcr-2021-247482 | PMID 35131796 Get It

Stiff-person syndrome (SPS) is a rare, autoimmune, neurological disorder that often occurs concurrently with other autoimmune disorders, such as type 1 diabetes mellitus, pernicious anaemia, vitiligo and Hashimoto’s thyroiditis. It also can manifest as a paraneoplastic syndrome. Although SPS classically presents with truncal and appendicular stiffness and lumbar hyperlordosis, it can present focally in a single limb (termed stiff-limb syndrome). Here, we describe a woman with stiff-limb syndrome who initially presented with concerns about right foot swelling and pain. She also was positive for anti-GAD65 (anti-GAD2) antibodies. With treatment, she regained the ability to drive and ambulate without a walker, and she had a noted reduction in stimulus-induced spasms.
Consensus Recommendation for Mouse Models of Ocular Hypertension to Study Aqueous Humor Outflow and Its Mechanisms
McDowell, Colleen M , Kizhatil, Krishnakumar , Elliott, Michael H. , Overby, Darryl R. , Sherwood, Joseph M. , Millar, J. Cameron , Kuehn, Markus H. , Zode, Gulab , Acott, Ted S. , Anderson, Michael G. , Bertrand, Jacques, Borrás, Terete, Bovenkamp, Diane E. , Cheng, Lin , Danias, John, Ieso, Michael L. De , Du, Yiqin , Faralli, Jennifer A., Fuchshofer, Rudolf , Ganapathy, Preethi S. , Gong, Haiyan , Hernandez, Humberto , John, Simon W. M. , Kaufman, Paul L., Keller, Kate E. , Kelley, Mary J. , Kelly, Ruth A. , Križaj, David , Kumar, Ajay , Leonard, Brian C. , Liu, Katy C., López, Navita N., Mao, Weiming , Mavlyutov, Timur, McDonnell, Fiona , Mzyk, Philip , Nartey, Andrews , Pasquale, Louis R. , Patel, Gaurang , Pattabiraman, Padmanabhan P. , Peters, Donna M. , Raghunathan, Vijaykrishna, Rao, Ponugoti Vasantha , Rayana, Naga Pradeep , Raychaudhuri, Urmimala, Reina‐Torres, Ester , Rhee, Douglas J. , Chowdhury, Uttio Roy, Samples, John R., Samples, E. Griffen, Sharif, Najam A. , Schuman, Joel S. , Stevenson, Cooper H., Soundararajan, Avinash , Subramanian, Preeti, Sugali, Chenna Kesavulu , Sun, Yang , Torrejon, Karen Y., Vahabikashi, Amir , Vranka, Janice A., Wang, Ting , Willoughby, Colin E. , Chen, Xin , Yun, Hongmin , Fautsch, Michael P. , Tamm, Ernst R. , Clark, Abbot F. , Ethier, C. Ross , Schuman, Joel S , Bhattacharya, Sanjoy K. , Bertrand, Jacques A., Herberg, Samuel , Humphries, Peter , Lieberman, Raquel L. , Liton, Paloma B. , Liu, Yutao , McLellan, Gillian J. , Raghunathan, Vijay Krishna , Rao, Ponugoti Vasantha , Ren, Ruiyi , Sheffield, Val C. , Toris, Carol B. , Zhang, Hao F. , Stamer, William Daniel

Mayo Clinic

Investigative Opthalmology & Visual Science | February 7, 2022 | Volume: 63 | Issue: 2 | Pages: 12

10.1167/iovs.63.2.12 | PMID 35129590 Get It

Emergent players in renovascular disease
Barsom, Samer Hani, Glasstetter, Logan M., Siddiqi, Sarosh , Rajagopalan, Kamalnath Sankaran, Eirin, Alfonso , Lerman, Lilach O. , Barsom, Samer H, Eirin, Alfonso

Mayo Clinic

Clinical Science | February 7, 2022 | Volume: 136 | Issue: 3 | Pages: 239-256

10.1042/cs20210509 | PMID 35129198 Get It

Abstract Renovascular disease (RVD) remains a common etiology of secondary hypertension. Recent clinical trials revealed unsatisfactory therapeutic outcomes of renal revascularization, leading to extensive investigation to unravel key pathophysiological mechanisms underlying irreversible functional loss and structural damage in the chronically ischemic kidney. Research studies identified complex interactions among various players, including inflammation, fibrosis, mitochondrial injury, cellular senescence, and microvascular remodeling. This interplay resulted in a shift of our understanding of RVD from a mere hemodynamic disorder to a pro-inflammatory and pro-fibrotic pathology strongly influenced by systemic diseases like metabolic syndrome (MetS), hypertension, diabetes mellitus, and hyperlipidemia. Novel diagnostic approaches have been tested for early detection and follow-up of RVD progression, using new imaging techniques and biochemical markers of renal injury and dysfunction. Therapies targeting some of the pathological pathways governing the development of RVD have shown promising results in animal models, and a few have moved from bench to clinical research. This review summarizes evolving understanding in chronic ischemic kidney injury.
The Intergluteal Fat Stripe in Patients With Hip Abductor Tears
Beicker, Clint, Hudspeth, L. Jared, Shanley, Ellen , Tokish, John M. , Folk, Jason, Hudspeth, L. Jared

Mayo Clinic

Orthopaedic Journal of Sports Medicine | February 7, 2022 | Volume: 10 | Issue: 2 | Pages: No page available

10.1177/23259671211068030 | PMID 35155703 Get It

Background: With a hip abductor tendon tear, widening of the intergluteal space, or “fat stripe,” is a characteristic change seen in and around the gluteus medius and minimus. Purpose: To determine the relationship of the intergluteal fat stripe in hips with pathologic abductor tears compared with the contralateral side and to evaluate the association of fat stripe size with hip-specific patient-reported outcome measures. Study Design: Case series; Level of evidence, 4. Methods: Of the 43 patients (42 female, 1 male; mean age, 56.6 years; range, 38-85 years) who underwent endoscopic gluteus medius repair, 19 met inclusion criteria of preoperative bilateral hip magnetic resonance imaging (MRI) scans and 2-year follow up. A single board-certified fellowship-trained orthopaedic surgeon (J.F.), who was blinded to outcomes, evaluated the MRI scans to measure the intergluteal fat stripe on the operative and nonoperative sides. The 2-year postoperative International Hip Outcome Tool (iHOT-12) and modified Harris Hip Score (mHHS) values were analyzed to determine their relationship to the size of the fat stripe. Statistical analysis was performed using a paired t test, and associations were determined using Pearson product correlation as well as nonparametric measurements. Results: The size of the intergluteal fat stripe differed significantly between the operative and nonoperative sides. The area of the fat stripe on the operative side was 645.73 ± 513.09 mm 2 , and on the nonoperative side it was 313.47 ± 360.71 mm 2 , an average of 332.36 mm 2 greater than the nonoperative side ( P = .02). The width of the fat stripe was 9.10 ± 4.60 mm on the operative side and 5.15 ± 3.87 mm on the nonoperative side, 3.95 mm greater than the nonoperative side ( P < .01). There was no correlation between the width or area of the fat stripe on the operative side and iHOT-12 or mHHS values at 2-year follow-up. Conclusion: The study findings indicated that the intergluteal fat stripe is significantly wider and has a significantly larger area in hips with abductor tears compared with unaffected hips. This did not correlate with 2-year patient-reported outcomes.
The subjectively perceived injectability as an early indicator for adverse events?
Alfertshofer, Michael , Sattler, Gerhard, Frank, Konstantin , Melnikov, Dimitry V., Freytag, Lysander, Mercado‐Perez, Arnaldo , Hargiss, J. Blade , Cotofana, Sebastian , Alfertshofer, Michael , Hargiss, John Blade , Dumbrava, Mihai , Cotofana, Sebastian , Dumbravă, Mihai

Mayo Clinic

Journal of Cosmetic Dermatology | February 7, 2022 | Volume: 21 | Issue: 9 | Pages: 3943-3948

10.1111/jocd.14697 | PMID 35128773 Get It

AbstractBackgroundWith an increasing demand of aesthetic soft‐tissue filler treatments, the occurrence of adverse events rises likewise. An optimized injection algorithm adapted to product characteristics (eg, rheology) of the soft‐tissue filler is crucial in order to ensure satisfying clinical outcomes and high patient safety.ObjectiveTo identify a subjective feedback mechanism for the avoidance of adverse events after soft‐tissue filler injection procedures.MethodsA retrospective data analysis of n = 387 aesthetic treatments performed on n = 291 patients (4 males, 287 females) with different soft‐tissue fillers with regard to loss of volume (filling effect), injected layer, injectability (“ease of injection”), injected volume, and injection technique was conducted.ResultsThe subjectively perceived injectability during the injection process was statistically significantly related to G‐Prime value with rs = 0.101 with p = 0.048, indicating an increased difficulty while injecting products with higher G‐Prime. The occurrence of adverse events was also statistically significantly related to the injectability: injections with increased subjectively perceived difficulty showed increasing odds of developing adverse events by OR 0.157 with p = 0.002.ConclusionInjections that were subjectively more difficult to perform are more likely to develop adverse events. Respecting the layered arrangement of the face, the recommended and approved depth and facial region for each specific treatment enable practitioners to achieve satisfying outcomes while keeping the rate of adverse events low.
Atypical Causes of Dyspnea
Hoffman, Ryan J., Garner, Hillary W., Rojas, Carlos A., Grage, Rolf A., Sonavane, Sushilkumar K., Johnson, Elizabeth M., Mergo, Patricia J., Walker, Christopher M., Stowell, Justin T., Hoffman, Ryan J., Garner, Hillary W., Rojas, Carlos A., Grage, Rolf A., Sonavane, Sushilkumar K., Johnson, Elizabeth M., Mergo, Patricia J., Walker, Christopher M., Stowell, Justin T.

Mayo Clinic

Journal of Thoracic Imaging | February 7, 2022 | Volume: 37 | Issue: 4 | Pages: W45-W55

10.1097/rti.0000000000000641 | PMID 35213124 Get It

Dyspnea is a common presenting symptom among patients with cardiopulmonary diseases. However, several neuromuscular and chest wall conditions are often overlooked and under-recognized causes of dyspnea. These disorders frequently adversely affect the structure and function of the ventilatory pump (diaphragm, accessory muscles of ventilation) and can precipitate respiratory failure despite normal lung parenchyma. Weakened musculature impairs clearance of airway secretions leading to aspiration and pneumonia, further compromising respiratory function. Radiologists should be aware of the pathophysiology and imaging manifestations of these conditions and might suggest them to be causes of dyspnea which otherwise may not have been considered by referring clinicians.